Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica

Vaccine

Volumn 26, Issue 37, 2008, Pages 4795-4808

  Herrero, Rolando ^a   Hildesheim, Allan ^b   Rodríguez, Ana C ^a,b   Wacholder, Sholom ^b   Bratti, Concepción ^a   Solomon, Diane ^b   González, Paula ^a   Porras, Carolina ^a   Jiménez, Silvia ^a   Guillen, Diego ^a   Morales, Jorge ^a   Alfaro, Mario ^a   Cyr, Jean ^c   Morrisey, Kerrygrace ^d   Estrada, Yenory ^a   Cortés, Bernal ^a   Morera, Lidia Ana ^a   Freer, Enrique ^e   Schussler, John ^c   Schiller, John ^b   Lowy, Douglas ^b   Schiffman, Mark ^b   more..

^a PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^b NATIONAL CANCER INSTITUTE   (United States)

^c INFORMATION MANAGEMENT SERVICES INC   (United States)

^d WESTAT   (United States)

^e UNIVERSIDAD DE COSTA RICA   (Costa Rica)

Author keywords

Clinical trial; Costa Rica; HPV vaccine

Indexed keywords

HEPATITIS A HEPATITIS B VACCINE; ORAL CONTRACEPTIVE AGENT; WART VIRUS VACCINE;

ADULT; ARTICLE; CELLULAR IMMUNITY; CHLAMYDIA TRACHOMATIS; CLINICAL PROTOCOL; CLINICAL TRIAL; COMMUNITY PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COSTA RICA; CYTOPATHOLOGY; DOUBLE BLIND PROCEDURE; FEMALE; GONORRHEA; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; METHODOLOGY; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; VIRUS DETECTION;

ADOLESCENT; ADULT; CERVIX UTERI; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; COSTA RICA; DOUBLE-BLIND METHOD; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNIZATION, SECONDARY; LONGITUDINAL STUDIES; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; RANDOM ALLOCATION; UTERINE CERVICAL NEOPLASMS;

EID: 49749134300     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.002     Document Type: Article

References (33)

1. Parkin D.M., and Bray F. Chapter 2: The burden of HPV - related cancers. Vaccine 24S3 (2006) 11-25
2. Denny L., Quinn M., and Sankaranarayanan R. Chapter 8: screening for cervical cancer in developing countries. Vaccine 24 (2006) 71-77
3. Vizcaino A.P., Moreno V., Bosch F.X., Munoz N., Barros-Dios X.M., Borras J., et al. International trends in incidence of cervical cancer: II Squamous-cell carcinoma. Int J Cancer 86 3 (2000) 429-435
4. Cogliano V., Baan R., Straif K., Grosse Y., Secretan B., and El Ghissassi F. WHO International Agency for Research on Cancer Carcinogenicity of human papillomaviruses. Lancet Oncol 6 4 (2005) 204
5. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 Nov. (21) (2002) 1645-1651
6. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4, 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 9518 (2006) 1247-1255
7. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 24 27-28 (2006) 5571-5583
8. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 9580 (2007) 2161-2170
9. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., and Unger E.R. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56 (2007) 1-24 (RR-2)
10. Paavonen J., and Lehtinen M. Introducing human papillomavirus vaccines - questions remain. Ann Med 40 3 (2008) 62-66
11. Herrero R., Schiffman M.H., Bratti C., Hildesheim A., Balmaceda I., Sherman M., et al. Design and methods of a population-based cohort study of cervical neoplasia in a rural province of Costa Rica: The Guanacaste Project. Rev Panam Salud Publica. 1 5 (1997) 362-375
12. Bratti C., Rodríguez A.C., Schiffman M., Hildesheim A., Morales J., Alfaro M., et al. Description of a seven-year prospective study of HPV infection and cervical neoplasia among 10 000 women in Guanacaste Costa Rica. Rev Panam Salud Publica 15 2 (2004) 75-89
13. Schiffman M., Herrero R., Hildesheim A., Sherman M.E., Bratti M., Wacholder S., et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 283 1 (2000) 87-93
14. Schiffman M., Castle P.E., Jeronimo J., Rodríguez A.C., and Wacholder S. Human papilomavirus and cervical cancer. Lancet 370 9590 (2007) 890-907 Review
15. Hildesheim A., Herrero R., Wacholder S., Bratti C., Sherman M., Lorincz A.T., et al. HPV cofactors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer 84 (2001) 1219-1226
16. Ferreccio C., Bratti C., Sherman M.E., Herrero R., Wacholder S., Hildesheim A., et al. A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer. Cancer Epidemiol Biomarkers Prev 12 9 (2003) 815-823
17. Herrero R., Hildesheim A., Bratti C., Sherman M.E., Hutchinson M., Morales J., et al. Population-based study of Human Papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 92 6 (2000) 464-474
18. Herrero R., Castle P.E., Schiffman M., Bratti M.C., Hildesheim A., Morales J., et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste Costa Rica. J Infect Dis 191 11 (2005) 1796-1807
19. Garcia-Pineres A.J., Hildesheim A., Herrero R., Trivett M., Williams M., Atmetlla I., et al. Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. Cancer Res 66 22 (2006) 11070-11076
20. Rodríguez A.C., Schiffman M., Herrero R., Wacholder S., Burk R., and On behalf of the Proyecto Epidemiologico Guanacaste Group. Rapid clearance of HPV should lead to clinical focus on persistent infections, not one-time detection. J Natl Cancer Inst 100 7 (2008) 513-517
21. Hildesheim A., Herrero R., Wacholder S., Rodríguez A.C., Solomon D., Bratti M.C., et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infeccion. JAMA 298 7 (2007) 743-753
22. Porras C., Safaeian M., González P., Hildesheim A., Silva S., Schiffman M., et al., Costa Rica HPV Vaccine Trial (CVT) Group. Epidemiology of genital chlamydia trachomatis infection among young women in Costa Rica. Sex Transm Dis 35 5 (2008) 461-468
23. Wright Jr. T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., and Solomon D. for the 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 197 Oct 4 (2007) 346-355 Review
24. Kleter B., van Doorn L.J., ter Schegget J., Schrauwen L., van Krimpen K., Burger M., et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 153 6 (1998) 1731-1739
25. Kleter B., van Doorn L.J., Schrauwen L., Molijn A., Sastrowijoto S., ter Schegget J., et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 37 8 (1999) 2508-2517
26. van Doorn L.J., Molijn A., Kleter B., Quint W., and Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 44 9 (2006) 3292-3298
27. Baay M.F., Quint W.G., Koudstaal J., Hollema H., Duk J.M., Burger M.P., et al. Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J Clin Microbiol 34 Mar. (3) (1996) 745-747
28. Safaeian M., Herrero R., Hildesheim A., Quint W., Freer E., Van Doorn L.J., et al. Comparison of the SPF10/LiPA System to the HC2 Assay for Detection of Carcinogenic HPV Genotypes among 5683 Young Women in Guanacaste Costa Rica. J Clin Microbiol 45 5 (2007) 1447-1454
29. 25 and linear array assays for detection of HPV genotypes, submitted.
30. Castle P.E., Hillier S.L., Rabe L.K., Hildesheim A., Herrero R., Bratti M.C., et al. An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol Biomarker Prev 10 10 (2001) 1021-1027
31. Schiffman M., Weeler C.M., Dasgupta A., Solomon D., Castle P.E., and the ALTS Group. A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears. Am J Clin Pathol 124 5 (2005) 722-732
32. Franceschi S., Herrero R., Clifford G.M., Snijders P.J.F., Arslan A., Hoang P.T., et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 119 (2006) 2677-2684
33. Schiller J., Castellsagué X., Villa L., and Hildesheim A. An update of Prophylactic Human Papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26 Suppl 10 (2008) K52-K60